Physician profile
Hin Cheung
NPI 1548677388
$3,232.57
in general payments reported to CMS, 2019-2025
18 companies · $701 in 2025
The $701 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $74.48 · 2021: $929 · 2022: $402 · 2023: $308 · 2024: $541 · 2025: $701.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,549.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,549.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,007.43 | 2021-2022 | |
| Alcon Vision LLC | $367.87 | 2019-2025 | Rocklatan |
| Bausch & Lomb Americas INC. | $217.46 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $188.99 | 2025 | |
| Johnson & Johnson Vision Care, INC. | $165.85 | 2023-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $158.70 | 2019-2020 | |
| Biotissue Holdings INC. | $152.59 | 2024 | |
| Mallinckrodt Hospital Products INC. | $124.29 | 2024 | Acthar |
| Apellis Pharmaceuticals, INC. | $113.81 | 2025 | |
| Oyster Point Pharma, INC. | $98.56 | 2022 | |
| Rxsight INC | $95.61 | 2023 | Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens |
| Astellas Pharma Global Development | $91.94 | 2025 | Izervay |
| Lkc Technologies, INC. | $83.24 | 2024 | |
| Glaukos Corporation | $82.85 | 2019 | |
| Sun Pharmaceutical Industries INC. | $82.79 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Quidel Corporation | $78.63 | 2022 | |
| Horizon Therapeutics Plc | $64.50 | 2022 | |
| Coopervision INC. | $57.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hin Cheung listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.